A clinical study to evaluate Safety, In-Use Tolerability and Efficacy of HTSS-052203 in reducing the facial dark spots in Healthy Adult Subjects.

Himalaya Wellness Company0 个研究点目标入组 42 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1) Subject has at least 2 dark spots on the face (suntan, blemishes, sunspots and age-spots). Preferably equal number of subjects will be recruited in all indications.
•2) Subjects with mild to moderate dark spots as per Investigator global assessment (IGA).
•3) Subjects with oily skin having Sebumeter measurement > 180 (Î¼g/cm2).

•1) Subjects having any active dermatological skin diseases (e.g., psoriasis, atopic dermatitis, rosacea etc.), that might interfere with clinical assessments.
•2) Subjects who are receiving topical or systemic treatments / undergoing skin lightening treatment.
•3) Subjects receiving medications (e.g., steroids or antihistamines) which would compromise the study.
•4) Subjects with chronic illness which may influence the cutaneous state.
•5) Subjects having history of diabetes, acute cardiac and circulatory diseases, HIV, hepatitis.
•6) Subjects using other marketed anti-acne/anti-aging/skin lightening products during the study period or in the past 6 weeks.

发起方